DHEA

Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone predominantly synthesized in the adrenal cortex, serving as a precursor to sex steroids. Researchers primarily study DHEA for its potential roles in aging, cognitive function, and various pathophysiological conditions. Key findings indicate that DHEA levels decline with age and may be associated with markers of longevity, while its neurosteroidal properties suggest a possible influence on mood and cognitive health. Clinical evidence indicates that DHEA may have beneficial effects in individuals with adrenal insufficiency and could play a role in addressing cognitive disorders. Current research continues to explore its pharmacological applications and the implications of DHEA supplementation, particularly in relation to aging and systemic diseases.

Dehydroepiandrosterone (DHEA), also known as Prasterone or Intrarosa, is an endogenous steroid hormone predominantly synthesized in the adrenal cortex, with additional production in the gonads and central nervous system. It belongs to the class of sex hormones and is the most abundant steroid hormone in primates. DHEA levels peak in early adulthood and decline with age, which has led to its consideration as a potential biomarker of aging. Researchers have observed that DHEA plays a significant role in various physiological processes, including acting as a precursor to sex steroids and exhibiting neurosteroidal properties. It has been studied for its potential neuroprotective, pro-cognitive, anxiolytic, and antidepressant effects, as well as its influence on conditions such as atherosclerosis, cancer, diabetes, and obesity. The mechanism of action of DHEA is complex, involving conversion to sex steroids and interaction with specific membrane receptors in various tissues, including the brain, heart, and liver. Despite the absence of a specific intranuclear receptor, DHEA's effects are mediated through these pathways. Pharmacokinetically, DHEA is rapidly cleared from the blood, while its sulfate ester, DHEAS, has a slower clearance rate. Both compounds interconvert and can be metabolized to androstenedione, testosterone, and estrogens in peripheral tissues. Clinically, DHEA is used in hypoadrenal individuals and has been investigated for treating depression and cognitive disorders. In the US, it is available as a dietary supplement, though its use in healthy individuals is controversial due to potential adverse effects. The FDA has granted orphan drug status for its use in preventing bone mineral density loss in systemic lupus erythematosus patients taking glucocorticoids, but further research is needed to establish its efficacy in other conditions.

DHEA acts primarily by converting into sex steroids such as testosterone and estrogens. It also interacts with specific membrane receptors on endothelial cells, influencing various biological processes including neuroprotection and cognitive function enhancement.

DHEA primarily exerts its effects through conversion to sex steroids, which then activate androgen and estrogen receptors, engaging pathways such as androgen receptor signaling and estrogen receptor signaling. Additionally, DHEA has neurosteroidal properties, potentially interacting with specific membrane receptors in various tissues, including the central nervous system, although the exact receptors and signaling pathways remain incompletely understood. Its biological processes include modulation of cognition, mood, immune function, and metabolic regulation, highlighting its role as a neuroprotective and anxiolytic agent.

Current evidence is limited regarding the specific mechanisms of action of DHEA and its metabolites, particularly the identification of intranuclear receptors and their roles in various tissues. Further research is needed to clarify the long-term effects and safety of DHEA supplementation in healthy elderly populations, as existing randomized controlled trials have not demonstrated significant benefits and raised concerns about potential adverse effects. Additionally, larger studies focusing on diverse populations, including those with specific conditions like systemic lupus erythematosus and glucocorticoid treatment, are necessary to better understand the therapeutic potential and risks associated with DHEA and prasterone.